News
Key Points Moderna has struggled since COVID-19 vaccine demand has shrunk.The stock has correspondingly declined, as revenue has nosedived over the last few years.The long game is clinical trials in ...
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...
Hosted on MSN5mon
Why GSK plc (GSK) Is One of the Best Vaccine Stocks to Buy ... - MSNWe sifted through stock screeners, online rankings, and ETFs to compile a list of 20 vaccine stocks. We then selected the top 10 most popular stocks among elite hedge funds as of Q4 2024.
We sifted through stock screeners, online rankings, and ETFs to compile a list of 20 vaccine stocks. We then selected the top 10 most popular stocks among elite hedge funds as of Q4 2024.
We sifted through stock screeners, online rankings, and ETFs to compile a list of 20 vaccine stocks. We then selected the top 10 most popular stocks among elite hedge funds as of Q4 2024.
Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern. The United States is in the midst of an ...
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) ... Vaccine Stocks Rise on Growing Threat of Bird Flu Infections April 17, 2025 — 10:51 am EDT.
Vaccine Stocks Muted as Investors Assess Kennedy's Overhaul of Key Panel. By Reuters | June 10, 2025. By Reuters | June 10, 2025, at 9:30 a.m. Save. More.
Moderna's stock fell 13% to $27.18 in early trading while Novavax's stock slid 7% to $6.50. Shares of Vaxcyte sank 55% to $31.60 and shares of Sarepta Therapeutics slipped 7% to $65.71. Shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results